SecBot SecBot
SECBOTREPLAY Home › Report › NSPR

NSPR · Priced equity offering

InspireMD, Inc. · 424B5 filed Nov 12, 2026 at 17:24 ET

At the news

BEARISHIMPACT 6/10

424B5 filed Nov 12, 2026 at 17:24 ET

InspireMD filed a preliminary prospectus supplement for an underwritten offering of common stock, pre-funded warrants, and Series L warrants, with size and pricing left blank as 'Subject to Completion'. The offering follows the same day's Q3 earnings release showing an 11.1% YoY revenue decline to $2.24M, a net loss of $9.76M, and cash of $19.2M, alongside the recent FDA approval of CGuard Prime for TCAR. The company also disclosed a Nasdaq minimum bid price deficiency and a going concern risk.

  • Preliminary prospectus supplement for an underwritten offering of common stock, pre-funded warrants, and Series L warrants; size and price TBD.
  • Filed on the same day as Q3 2026 earnings: total revenue $2.24M, down 11.1% YoY; net loss $9.76M.
  • Cash and equivalents $19.2M as of September 30, 2026, down from $54.2M at December 31, 2025.
  • Received FDA approval of CGuard Prime for TCAR on November 9, 2026, expected to double U.S. addressable market.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access